Shares of Vertex Pharmaceuticals fell in trading after the company announced it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study for a rare disease that can lead to complications of the liver and lungs.

The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals Inc.’s Trikafta to treat cystic fibrosis in children aged 6 to 11 years old, making the cocktail therapy the first approved treatment for CF in that age group.

U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.

AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.

MorphoSys is acquiring Constellation Pharmaceuticals for about $1.7 billion and announced a partnership with Royalty Pharma for $1.425 billion up front.

The U.S. Supreme Court on June 1 declined to hear Johnson & Johnson’s bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products.

The U.S. Food and Drug Administration on May 28 approved Amgen Inc.’s drug Lumakras for lung cancer patients with a specific mutation in a gene known as KRAS whose disease has worsened after treatment with chemotherapy or other medicines.

Shares of Provention Bio Inc. plunged in trading after a Food and Drug Administration advisory committee narrowly supported the company’s diabetes prevention drug, teplizumab.

AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.

NGM Biopharmaceuticals’ aldafermin failed to hit the primary endpoint in the company’s Phase IIb ALPINE 2/3 trial for non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis.